Related Experiment Videos
Autocrine growth factors and neuroendocrine markers in the development of small-cell lung cancer
1Division of Clinical Sciences, National Naval Medical Center, USA.
Abstract:
Two different clinical trials using biological agents directed against an autocrine growth factor and a surface marker of neuroendocrine differentiation have been used for patients with relapsed small-cell lung cancer. In a phase II trial, an antibody (2A11) directed against the autocrine growth factor gastrin-releasing peptide has been used to treat patients with relapsed small-cell lung cancer. One of 12 evaluable patients treated with 2A11 250 mg/m2 three times weekly for 4 weeks achieved a complete response. An antibody directed against the neural cell adhesion molecule has been linked to a modified ricin molecule. This immunotoxin, N901-bR, has undergone phase I testing, and a recommended phase II dose of 30 micrograms/kg/day for 7 days by continuous infusion has been determined. In the phase I trial, one of 21 patients with relapsed or refractory small-cell lung cancer had a partial response to this treatment. Therefore, it appears that an antibody directed against an autocrine growth factor and an immunotoxin directed against a surface marker of neuroendocrine differentiation can inhibit the growth of small-cell lung cancer in vitro and in vivo; both produced some evidence of antitumor activity in patients. Further studies with agents directed against autocrine growth factors and surface markers of neuroendocrine differentiation appear warranted.
Insights
Novel biological agents targeting growth factors and cell markers show promise for relapsed small-cell lung cancer. Further research into these targeted therapies is warranted for improved patient outcomes.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- Small-cell lung cancer (SCLC) is an aggressive malignancy with limited treatment options for relapsed disease.
- Targeting autocrine growth factors and neuroendocrine differentiation markers represents a potential therapeutic strategy.
Purpose of the Study:
- To evaluate the efficacy and safety of two novel biological agents in patients with relapsed small-cell lung cancer.
- To assess an antibody targeting gastrin-releasing peptide (GRP) and an immunotoxin targeting the neural cell adhesion molecule (NCAM).
Main Methods:
- Phase II trial of antibody 2A11 (anti-GRP) in relapsed SCLC patients.
- Phase I trial of immunotoxin N901-bR (anti-NCAM) in relapsed/refractory SCLC patients to determine the recommended Phase II dose.
Main Results:
- One of 12 evaluable patients achieved a complete response with antibody 2A11.
- One of 21 patients achieved a partial response with immunotoxin N901-bR.
- Both agents demonstrated in vitro and in vivo inhibition of SCLC growth and some antitumor activity in patients.
Conclusions:
- Antibody 2A11 and immunotoxin N901-bR show preliminary antitumor activity in relapsed SCLC.
- Targeted therapies against autocrine growth factors and neuroendocrine markers warrant further investigation in SCLC.